Načítá se...
P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage non-small cell lung cancer (NSCLC). KRAS mutations have been reported as a negative prognostic and predictive factor in pati...
Uloženo v:
| Vydáno v: | Transl Lung Cancer Res |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Pioneer Bioscience Publishing Company
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367782/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB032 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|